Clinical Takeaway
In this small pilot trial, a single oral dose of 10 mg THC combined with 200 mg CBD reduced total sleep time by approximately 25 minutes in adults with diagnosed insomnia disorder, suggesting this combination did not improve and may have mildly disrupted objective sleep duration. High-density EEG allowed detailed measurement of sleep architecture changes, and next-day alertness was also assessed, providing a more complete picture of cannabinoid effects than self-report alone. Patients and clinicians should interpret these findings cautiously given the small sample size, but the results highlight that cannabinoid sleep aids do not consistently produce the benefits many users expect.
#9 Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.
Citation: Suraev Anastasia et al.. Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.. Journal of sleep research. 2026. PMID: 40631525.
Design: 5 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0
This pilot study provides the first objective neurophysiological data on how THC/CBD combinations affect sleep architecture and cortical activity in insomnia patients, filling a critical evidence gap for a widely used but understudied treatment. High-density EEG characterization of cannabinoid effects on sleep stages and spectral power enables clinicians to move beyond subjective reports and better understand the mechanistic basis for recommending or cautioning against these agents in insomnia management. These findings establish a methodological foundation for larger trials needed to determine whether cannabinoid-induced sleep changes translate to clinically meaningful improvements in daytime function and sustained therapeutic benefit.
Methodological Considerations:
- Self-reported outcomes — recall and social-desirability bias risk
Abstract: Cannabinoids, particularly Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), have gained popularity as alternative sleep aids; however, their effects on sleep architecture and next-day function remain poorly understood. Here, in a pilot trial, we examined the effects of a single oral dose containing 10 mg THC and 200 mg CBD (THC/CBD) on objective sleep outcomes and next-day alertness using 256-channel high-density EEG in 20 patients with DSM-5 diagnosed insomnia disorder (16 female; mean (SD) age, 46.1 (8.6) years). We showed that THC/CBD decreased total sleep time (-24.5 min, p = 0.05, d = -0.5) with no change in wake after sleep onset (+10.7 min, p > 0.05) compared to placebo. THC/CBD also significantly decreased time spent in REM sleep (-33.9 min, p < 0.001, d = -1.5) and increased latency to REM sleep (+65.6 min, p = 0.008, d = 0.7). High-density EEG analysis revealed regional decreases in gamma activity during N2 sleep, and in delta activity during N3 sleep, and a regional increase in beta and alpha activity during REM sleep. While there was no observed change in next-day objective alertness, a small but significant increase in self-reported sleepiness was noted with THC/CBD (+0.42 points, p = 0.02, d = 0.22). No changes in subjective sleep quality, cognitive performance, or simulated driving performance were observed. These findings suggest that a single dose of cannabinoids, particularly THC, may acutely influence sleep, primarily by suppressing REM sleep, without noticeable next-day impairment (≥ 9 h post-treatment). Australian New Zealand Clinical Trial Registry (ACTRN12619000714189) https://www.anzctr.org.au/.
😴 This pilot study provides encouraging preliminary data that a 10:20 THC-to-CBD ratio may improve sleep architecture in insomnia patients, but several important limitations warrant caution before clinical application. The small sample size of 20 patients, predominance of female participants (80%), and single-dose design limit generalizability and tell us little about efficacy with repeated dosing or long-term tolerability. Critical unknowns remain regarding next-day cognitive and motor effects, potential dependence with regular use, and how individual variation in cannabinoid metabolism might affect outcomes across diverse patient populations. While the high-density EEG methodology is a strength, the lack of longer-term safety data and potential confounders like baseline sleep architecture differences between responders and non-responders deserve attention in future larger trials. Clinically, this work suggests cannabinoids warrant further rigorous investigation for insomnia, but practitioners should continue counseling patients that first-line evidence-based treatments (CBT-I, sleep hygiene,